{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T21:17:53Z","timestamp":1793395073834,"version":"4.5.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:00:00Z","timestamp":1761868800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:00:00Z","timestamp":1761868800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Urol"],"DOI":"10.1007\/s00345-025-06006-4","type":"journal-article","created":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T10:41:51Z","timestamp":1761907311000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Updated cost-effectiveness analysis of first-line novel therapies in locally advanced or metastatic urothelial carcinoma across the UK, US, and China"],"prefix":"10.1007","volume":"43","author":[{"given":"Jingwen","family":"Lin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wu","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caicong","family":"You","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaobin","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maobai","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongfu","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,31]]},"reference":[{"issue":"19","key":"6006_CR1","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.1056\/NEJMoa2309863","volume":"389","author":"MS van der Heijden","year":"2023","unstructured":"van der Heijden MS, Sonpavde G, Powles T et al (2023) Nivolumab plus Gemcitabine-Cisplatin in advanced urothelial carcinoma. N Engl J Med 389(19):1778\u20131789. https:\/\/doi.org\/10.1056\/NEJMoa2309863","journal-title":"N Engl J Med"},{"issue":"10","key":"6006_CR2","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1056\/NEJMoa2312117","volume":"390","author":"T Powles","year":"2024","unstructured":"Powles T, Valderrama BP, Gupta S et al (2024) Enfortumab Vedotin and pembrolizumab in untreated advanced urothelial cancer. N Engl J Med 390(10):875\u2013888. https:\/\/doi.org\/10.1056\/NEJMoa2312117","journal-title":"N Engl J Med"},{"key":"6006_CR3","unstructured":"National Comprehensive Cancer Network (NCCN) (2024) Recently Published Guidelines. https:\/\/www.nccn.org\/guidelines\/recently-published-guidelines. Accessed Sept 24"},{"key":"6006_CR4","doi-asserted-by":"crossref","unstructured":"Powles T, Bellmunt J, Comperat E et al (2024) ESMO Clinical Practice Guideline interim update on first-line therapy in advanced urothelial carcinoma. Ann Oncol. ;35(6):485\u2013490. Published online June 1, 2024. https:\/\/www.esmo.org\/guidelines\/guidelines-by-topic\/esmo-clinical-practice-guidelines-genitourinary-cancers\/clinical-practice-guideline-bladder-cancer\/eupdate-advanced-urothelial-carcinoma-treatment-recommendations. Accessed Sept 24, 2024","DOI":"10.1016\/j.annonc.2024.03.001"},{"key":"6006_CR5","unstructured":"Chinese Society of Clinical Oncology (2025) Published online. Chinese Society of Clinical Oncology. https:\/\/www.csco.org.cn\/cn\/index.aspx.Accessed February 9"},{"issue":"21","key":"6006_CR6","doi-asserted-by":"publisher","first-page":"2112","DOI":"10.1016\/j.jacc.2023.03.415","volume":"81","author":"J Zheng","year":"2023","unstructured":"Zheng J, Sandhu AT (2023) The inflation reduction act expands prescription drug affordability: decades in the making. J Am Coll Cardiol 81(21):2112\u20132114. https:\/\/doi.org\/10.1016\/j.jacc.2023.03.415","journal-title":"J Am Coll Cardiol"},{"key":"6006_CR7","unstructured":"The White House (2025), May 12 Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients. The White House. https:\/\/www.whitehouse.gov\/presidential-actions\/2025\/05\/delivering-most-favored-nation-prescription-drug-pricing-to-american-patients\/. Accessed May 221, 2025"},{"key":"6006_CR8","unstructured":"U.S. Department of Health and Human Services (2025), May 20 HHS, CMS Set Most-Favored-Nation Pricing Targets to End Global Freeloading on American Patients. https:\/\/www.hhs.gov\/press-room\/cms-mfn-lower-us-drug-prices.html. Accessed May 21, 2025"},{"key":"6006_CR9","unstructured":"Pharmaguidelines (2024) Ensuring Equitable Access: An Overview of the NHS Drug Reimbursement Policy in the UK. Published online December 2. https:\/\/pharmaguidelines.co.uk\/2024\/12\/02\/ensuring-equitable-access-an-overview-of-the-nhs-drug-reimbursement-policy-in-the-uk\/. Accessed Feb 9, 2025"},{"key":"6006_CR10","unstructured":"UK Parliament. Select Committee on Public Accounts. Fifth Report of Session 2024\u201325. London: The Stationery Office (2025) https:\/\/publications.parliament.uk\/pa\/cm5901\/cmselect\/cmpubacc\/350\/report.html. Published January 29, 2025. Accessed Feb 9, 2025"},{"issue":"1","key":"6006_CR11","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1186\/s12913-024-11217-3","volume":"24","author":"J Wang","year":"2024","unstructured":"Wang J, Zhang S, Wang C, Li J, Wang R, Zhu L (2024) The vacated space of volume\/price of the drugs centralized procurement with quantity in secondary and above public hospitals of China. BMC Health Serv Res 24(1):771. https:\/\/doi.org\/10.1186\/s12913-024-11217-3","journal-title":"BMC Health Serv Res"},{"key":"6006_CR12","doi-asserted-by":"publisher","first-page":"1227102","DOI":"10.3389\/fpubh.2023.1227102","volume":"11","author":"Z Sun","year":"2023","unstructured":"Sun Z, Na X, Chu S (2023) Impact of china\u2019s National centralized drug procurement policy on pharmaceutical enterprises\u2019 financial performance: a quasi-natural experimental study. Front Public Health 11:1227102. https:\/\/doi.org\/10.3389\/fpubh.2023.1227102","journal-title":"Front Public Health"},{"key":"6006_CR13","unstructured":"KFF. FAQs about the Inflation Reduction Act\u2019s Medicare Drug Price Negotiation Program. Published online (2025) January https:\/\/www.kff.org\/medicare\/issue-brief\/faqs-about-the-inflation-reduction-acts-medicare-drug-price-negotiation-program\/ Accessed Mar 20, 2025"},{"key":"6006_CR14","unstructured":"Syenza (2025) Reevaluating NICE\u2019s Cost-Effectiveness Thresholds: The QALY Debate. Published online December 2024. https:\/\/news.syenza.com\/reevaluating-nices-cost-effectiveness-thresholds-qaly-debate\/. Accessed Mar 20"},{"issue":"10472","key":"6006_CR15","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/S0140-6736(24)02352-3","volume":"405","author":"H Naci","year":"2025","unstructured":"Naci H, Murphy P, Woods B, Lomas J, Wei J, Papanicolas I (2025) Population-health impact of new drugs recommended by the National Institute for health and care excellence in England during 2000-20: a retrospective analysis. Lancet 405(10472):50\u201360. https:\/\/doi.org\/10.1016\/S0140-6736(24)02352-3","journal-title":"Lancet"},{"issue":"1","key":"6006_CR16","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1186\/s12885-022-10350-8","volume":"22","author":"J Kang","year":"2022","unstructured":"Kang J, Cairns J (2022) Exploring uncertainty and use of real-world data in the National Institute for health and care excellence single technology appraisals of targeted cancer therapy. BMC Cancer 22(1):1268. https:\/\/doi.org\/10.1186\/s12885-022-10350-8","journal-title":"BMC Cancer"},{"key":"6006_CR17","unstructured":"Stanford Law School. Drug Centralized Procurement in China: Concerns and Implications for Drug Quality and Access. Published online February 18 (2025) https:\/\/law.stanford.edu\/2025\/02\/18\/drug-centralized-procurement-in-china-concerns-and-implications-for-drug-quality-and-access\/. Accessed Mar 9, 2025"},{"key":"6006_CR18","unstructured":"Powles T (2025), February 15 ASCO GU 2025: EV-302: Updated Analysis from the Phase 3 Global Study of Enfortumab Vedotin in Combination with Pembrolizumab (EV\u2009+\u2009P) vs Chemotherapy (Chemo) in Previously Untreated Locally Advanced or Metastatic Urothelial Carcinoma (la\/mUC). UroToday. https:\/\/www.urotoday.com\/conference-highlights\/asco-gu-2025\/asco-gu-2025-bladder-cancer\/158290-asco-gu-2025-ev-302-updated-analysis-from-the-phase-3-global-study-of-enfortumab-vedotin-in-combination-with-pembrolizumab-ev-p-vs-chemotherapy-chemo-in-previously-untreated-locally-advanced-or-metastatic-urothelial-carcinoma-la-muc.html. Accessed Mar 9, 2025"},{"issue":"1","key":"6006_CR19","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.jval.2021.10.008","volume":"25","author":"D Husereau","year":"2022","unstructured":"Husereau D, Drummond M, Augustovski F et al (2022) Consolidated health economic evaluation reporting standards (CHEERS) 2022 explanation and elaboration: a report of the ISPOR CHEERS II good practices task force. Value Health 25(1):10\u201331. https:\/\/doi.org\/10.1016\/j.jval.2021.10.008","journal-title":"Value Health"},{"issue":"1","key":"6006_CR20","doi-asserted-by":"publisher","first-page":"e17","DOI":"10.1016\/j.clgc.2020.07.006","volume":"19","author":"O Hale","year":"2021","unstructured":"Hale O, Patterson K, Lai Y et al (2021) Cost-effectiveness of pembrolizumab versus Carboplatin-based chemotherapy as First-line treatment of PD-L1-positive locally advanced or metastatic urothelial carcinoma ineligible for Cisplatin-based therapy in the united States. Clin Genitourin Cancer 19(1):e17\u201317e30. https:\/\/doi.org\/10.1016\/j.clgc.2020.07.006","journal-title":"Clin Genitourin Cancer"},{"key":"6006_CR21","unstructured":"Neumann PJ, Sanders GD et al (2016) Cost-effectiveness in health and medicine. Second edition. 2nd edition. New York: Oxford University Press"},{"key":"6006_CR22","doi-asserted-by":"publisher","first-page":"1464092","DOI":"10.3389\/fimmu.2024.1464092","volume":"15","author":"A Li","year":"2024","unstructured":"Li A, Wu M, Xie O et al (2024) Cost-effectiveness of first-line enfortumab Vedotin in addition to pembrolizumab for metastatic urothelial carcinoma in the united States. Front Immunol 15:1464092. https:\/\/doi.org\/10.3389\/fimmu.2024.1464092","journal-title":"Front Immunol"},{"key":"6006_CR23","doi-asserted-by":"publisher","unstructured":"Rieger C, Schl\u00fcchtermann J, Lehmann M et al Cost-effectiveness analysis in the new era of treatment strategies in metastatic urothelial carcinoma based on Checkmate-901 and EV302\/Keynote-A39. Eur Urol Oncol. 2024:S2588-9311(24)00231\u201300231 [pii]. https:\/\/doi.org\/10.1016\/j.euo.2024.10.003","DOI":"10.1016\/j.euo.2024.10.003"},{"issue":"1","key":"6006_CR24","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1186\/s12913-020-5050-9","volume":"20","author":"A Gandjour","year":"2020","unstructured":"Gandjour A (2020) Willingness to pay for new medicines: a step towards narrowing the gap between NICE and IQWiG. BMC Health Serv Res 20(1):343. https:\/\/doi.org\/10.1186\/s12913-020-5050-9","journal-title":"BMC Health Serv Res"},{"issue":"1","key":"6006_CR25","doi-asserted-by":"publisher","first-page":"e013070","DOI":"10.1136\/bmjgh-2023-013070","volume":"9","author":"L Xu","year":"2024","unstructured":"Xu L, Chen M, Angell B et al (2024) Establishing cost-effectiveness threshold in china: a community survey of willingness to pay for a healthylife year. BMJ Glob Health 9(1):e013070. https:\/\/doi.org\/10.1136\/bmjgh-2023-013070","journal-title":"BMJ Glob Health"},{"key":"6006_CR26","doi-asserted-by":"publisher","unstructured":"Jackson CH (2016) flexsurv: A Platform for Parametric Survival Modeling in R. J Stat Softw 70:i08 . https:\/\/doi.org\/10.18637\/jss.v070.i08.","DOI":"10.18637\/jss.v070.i08"},{"issue":"4","key":"6006_CR27","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1177\/0272989X21992297","volume":"41","author":"D Gallacher","year":"2021","unstructured":"Gallacher D, Kimani P, Stallard N (2021) Extrapolating parametric survival models in health technology assessment using model averaging: a simulation study. Med Decis Mak 41(4):476\u2013484. https:\/\/doi.org\/10.1177\/0272989X21992297","journal-title":"Med Decis Mak"},{"key":"6006_CR28","unstructured":"Human Mortality Database (2025) https:\/\/mortality.org. Accessed Jan 3"},{"key":"6006_CR29","unstructured":"National Medical Security Administration (2024), December 14 Comprehensively Implementing the Spirit of the Central Economic Work Conference to Promote High-Quality Development of Medical Security. https:\/\/www.gov.cn\/lianbo\/bumen\/202412\/content_6993301.htm. Accessed Jan 3, 2025"},{"key":"6006_CR30","unstructured":"Centers for Medicare & Medicaid Services (CMS) (2025) Medicare Physician Fee Schedule Relative Value Files. https:\/\/www.cms.gov\/medicare\/payment\/fee-schedules\/physician\/pfs-relative-value-files\/rvu24a. Accessed Jan 3"},{"key":"6006_CR31","unstructured":"British National Formulary (BNF) (2025) https:\/\/bnf.nice.org.uk\/. Accessed Jan 24"},{"key":"6006_CR32","unstructured":"Yaozh Database. Pharmaceutical Bidding Information. May 17 (2025) from https:\/\/db.yaozh.com\/yaopinzhongbiao. Accessed Mar 8 2025"},{"issue":"5","key":"6006_CR33","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1200\/JCO.1997.15.5.1853","volume":"15","author":"JA McCaffrey","year":"1997","unstructured":"McCaffrey JA, Hilton S, Mazumdar M et al (1997) Phase II trial of docetaxel in patients with advanced or metastatic transitional-cell carcinoma. J Clin Oncol 15(5):1853\u20131857. https:\/\/doi.org\/10.1200\/JCO.1997.15.5.1853","journal-title":"J Clin Oncol"},{"issue":"4","key":"6006_CR34","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1200\/JCO.2002.20.4.937","volume":"20","author":"DJ Vaughn","year":"2002","unstructured":"Vaughn DJ, Broome CM, Hussain M, Gutheil JC, Markowitz AB (2002) Phase II trial of weekly Paclitaxel in patients with previously treated advanced urothelial cancer. J Clin Oncol 20(4):937\u2013940. https:\/\/doi.org\/10.1200\/JCO.2002.20.4.937","journal-title":"J Clin Oncol"},{"issue":"11","key":"6006_CR35","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1056\/NEJMoa1613683","volume":"376","author":"J Bellmunt","year":"2017","unstructured":"Bellmunt J, de Wit R, Vaughn DJ et al (2017) Pembrolizumab as Second-Line therapy for advanced urothelial carcinoma. N Engl J Med 376(11):1015\u20131026. https:\/\/doi.org\/10.1056\/NEJMoa1613683","journal-title":"N Engl J Med"},{"issue":"5","key":"6006_CR36","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/j.euo.2018.09.009","volume":"2","author":"K Patterson","year":"2019","unstructured":"Patterson K, Prabhu V, Xu R et al (2019) Cost-effectiveness of pembrolizumab for patients with Advanced, Unresectable, or metastatic urothelial cancer ineligible for Cisplatin-based therapy. Eur Urol Oncol 2(5):565\u2013571. https:\/\/doi.org\/10.1016\/j.euo.2018.09.009","journal-title":"Eur Urol Oncol"},{"issue":"8","key":"6006_CR37","doi-asserted-by":"publisher","first-page":"459","DOI":"10.2217\/fon-2023-0372","volume":"20","author":"S Critchlow","year":"2024","unstructured":"Critchlow S, Bullement A, Crabb S et al (2024) Cost-effectiveness analysis for avelumab first-line maintenance treatment of advanced urothelial carcinoma in Scotland. Future Oncol 20(8):459\u2013470. https:\/\/doi.org\/10.2217\/fon-2023-0372","journal-title":"Future Oncol"},{"key":"6006_CR38","unstructured":"International Monetary Fund (IMF) World Economic Outlook (October 2024): GDP per capita, current prices. IMF DataMapper. https:\/\/www.imf.org\/external\/datamapper\/NGDPDPC@WEO\/OEMDC\/ADVEC\/WEOWORLD\/GBR. Accessed Jan 13, 2025"},{"key":"6006_CR39","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-319-15744-3_7","author":"R Edlin","year":"2015","unstructured":"Edlin R, Mccabe C, Hulme C, Hall P, Wright J (2015) Probability distributions for cost and utility parameters. Springer Int Publishing. https:\/\/doi.org\/10.1007\/978-3-319-15744-3_7","journal-title":"Springer Int Publishing"},{"key":"6006_CR40","unstructured":"KPMG Switzerland (2025) (n.d.). Pathway to success in outcome-based contracting: Navigating payer needs. https:\/\/assets.kpmg.com\/content\/dam\/kpmgsites\/ch\/pdf\/pathway-to-success-in-outcome-based-contracting.pdf. Accessed May 13"},{"key":"6006_CR41","unstructured":"NHS England (2025) (n.d.). NHS Commercial Framework for New Medicines. https:\/\/www.england.nhs.uk\/long-read\/nhs-commercial-framework-for-new-medicines\/. Accessed May 13"},{"issue":"7","key":"6006_CR42","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.2105\/AJPH.2015.302554","volume":"105","author":"OD Williams","year":"2015","unstructured":"Williams OD, Ooms G, Hill PS (2015) Cautionary notes on a global tiered pricing framework for medicines. Am J Public Health 105(7):1290\u20131293. https:\/\/doi.org\/10.2105\/AJPH.2015.302554","journal-title":"Am J Public Health"},{"key":"6006_CR43","doi-asserted-by":"publisher","first-page":"1412292","DOI":"10.3389\/fphar.2024.1412292","volume":"15","author":"M You","year":"2024","unstructured":"You M, Zheng Q, He Y (2024) Enfortumab Vedotin plus pembrolizumab as a first-line treatment for advanced urothelial carcinoma: a cost-effectiveness analysis from China based on the EV-302 trial. Front Pharmacol 15:1412292. https:\/\/doi.org\/10.3389\/fphar.2024.1412292","journal-title":"Front Pharmacol"}],"container-title":["World Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-025-06006-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00345-025-06006-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-025-06006-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T23:03:06Z","timestamp":1767999786000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00345-025-06006-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,31]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["6006"],"URL":"https:\/\/doi.org\/10.1007\/s00345-025-06006-4","relation":{},"ISSN":["1433-8726"],"issn-type":[{"value":"1433-8726","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,31]]},"assertion":[{"value":"23 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The authors declare that they have obtained written consent from all participants involved in the study to publish the data and findings.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human ethics and consent to participate declaration"}}],"article-number":"657"}}